Linagliptin as a modulator of vascular inflammation in patients with type 2 diabetes mellitus
Latest Information Update: 18 Apr 2017
At a glance
- Drugs Linagliptin (Primary)
- Indications Coronary artery disease; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms Lina-Plaque
- 02 Dec 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
- 04 Nov 2014 Planned End Date changed from 1 Jun 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov
- 04 Nov 2014 Planned primary completion date changed from 1 Jun 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov